Pittsburgh-based BlueSphere Bio, a clinical stage drug development company focused on novel T cell based therapies, recently named Dr. Alan Korman as chief scientific officer.
Korman has more than more than 30 years of immunology and drug discovery experience. He has been on the BlueSphere board of directors since 2020.
Korman began his career in the pharmaceutical industry. Before joining the board, Korman was Vir Biotechnology senior vice president of human immunology, Bristol-Myers Squibb vice president of immuno-oncology discovery and Medarex vice president of discovery research.
“We are honored to have Dr. Korman as our new chief scientific officer,” Keir Loiacono, BlueSphere Bio CEO, said. “His leadership and esteemed track record pioneering transformational therapies will be instrumental in advancing our pipeline with an increased focus on TCR-based modalities, including bispecifics. “Alan’s deep expertise in biologics and drug discovery will further position BlueSphere to ensure we are pursuing novel tumor antigens deployable in next generation treatment modalities. This will include overseeing our current discovery program in dark matter antigens.”
Korman has a Ph.D. in cellular and developmental biology from Harvard University. He holds more than 30 patents.
BlueSphere Bio was founded by UPMC Enterprises, the commercialization and venture capital arm of the Pittsburgh-based health system.